Paul Grayburn, MD, FACC, FAHA, FASE
Dr. Paul Grayburn did his general cardiology fellowship under the tutelage of Dr. Anthony N. DeMaria at the University of Kentucky from 1984-1986, followed by a year of interventional cardiology training with Drs. David C. Booth and Cindy Grines. In 1988, he was recruited to the University of Texas Southwestern Medical Center by Dr. James T. Willerson, where he served on the faculty for 15 years. During that time, he was Director of the Echocardiography Laboratories at UT Southwestern, and Chief of Cardiology at the Dallas VA Medical Center, where he also practiced interventional cardiology. In 2002, Dr. Grayburn moved to Baylor University Medical Center to accept the Paul J. Thomas Chair in Cardiology Research and Education. He has published > 450 papers in the medical literature and is currently Associate Editor of the American Journal of Cardiology, JACC: Cardiovascular Imaging and Structural Heart. He has held a NIH K24 grant for mentoring junior faculty and an R01 grant “Functional MR in Ischemic Cardiomyopathy” for 3D TEE evaluation of the mechanisms of functional MR in the STICH Trial. He also served as a Core Lab Director for Dr. Christopher Newgard’s program project grant “Novel Therapies for NIDDM.” He has pioneered the use of ultrasound-targeted microbubble destruction for gene therapy. This work was recently highlighted by Dr. Grayburn in the opening session of the 2019 AHA Scientific Sessions in Philadelphia. He has served on multiple committees for the American Society of Echocardiography, including the Task Force for Quantitation of Valvular Regurgitation. He is currently serving on Steering Committees for several clinical trials in structural heart intervention, including national PI for the CLASP IIF study. His background in both interventional cardiology and echocardiography, including intraoperative TEE during surgical mitral valve repair, give him a unique insight into percutaneous mitral valve therapies. Dr. Grayburn is a consultant for Abbott Vascular, Edwards, Gore, Medtronic, 4C Medical and receives grant support from the NIH, Abbott Vascular, Boston Scientific, Edwards, Medtronic, Cardiovalve, Neochord and Gore.